H
Heather J. Sutherland
Researcher at Vancouver General Hospital
Publications - 185
Citations - 9482
Heather J. Sutherland is an academic researcher from Vancouver General Hospital. The author has contributed to research in topics: Transplantation & Multiple myeloma. The author has an hindex of 47, co-authored 177 publications receiving 8929 citations. Previous affiliations of Heather J. Sutherland include BC Cancer Research Centre & BC Cancer Agency.
Papers
More filters
Journal ArticleDOI
Characterization and Partial Purification of Human Marrow Cells Capable of Initiating Long-Term Hematopoiesis In Vitro
Heather J. Sutherland,Connie J. Eaves,Allen C. Eaves,Wieslawa H. Dragowska,Peter M. Lansdorp +4 more
TL;DR: The ability to purify these two populations independently shows that the LTC and clonogenic assays identify distinct, although not necessarily nonoverlapping cell types in human marrow.
Journal ArticleDOI
Functional characterization of individual human hematopoietic stem cells cultured at limiting dilution on supportive marrow stromal layers.
TL;DR: The availability of a system for quantitative analysis of the proliferative and differentiative behavior of this newly defined compartment of primitive human hematopoietic cells should facilitate future studies of specific genetic or microenvironmental parameters involved in the regulation of these cells.
Journal ArticleDOI
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
Sagar Lonial,Brendan M. Weiss,Saad Z. Usmani,Seema Singhal,Ajai Chari,Nizar J. Bahlis,Andrew Belch,Amrita Krishnan,Robert Vescio,Maria-Victoria Mateos,Amitabha Mazumder,Robert Z. Orlowski,Heather J. Sutherland,Joan Bladé,Emma C. Scott,Albert Oriol,Jesus G. Berdeja,Mecide Gharibo,Don A. Stevens,Richard Leblanc,Michael Sebag,Natalie S. Callander,Andrzej Jakubowiak,Darrell White,Javier de la Rubia,Paul G. Richardson,Steen Lisby,Huaibao Feng,Clarissa M. Uhlar,Imran Khan,Tahamtan Ahmadi,Peter M. Voorhees +31 more
TL;DR: Daratumumab monotherapy showed encouraging efficacy in heavily pretreated and refractory patients with multiple myeloma, with a favourable safety profile in this population of patients.
Journal ArticleDOI
Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression
Robert Z. Orlowski,Arnon Nagler,Pieter Sonneveld,Joan Bladé,Roman Hájek,Andrew Spencer,Jesús F. San Miguel,Tadeusz Robak,Anna Dmoszynska,Noemi Horvath,Ivan Spicka,Heather J. Sutherland,Alexander Suvorov,Sen H. Zhuang,Trilok V. Parekh,Liang Xiu,Zhilong Yuan,Wayne Rackoff,Jean Luc Harousseau +18 more
TL;DR: PLD with bortzomib is superior to bortezomib monotherapy for the treatment of patients with relapsed or refractory multiple myeloma, and the combination therapy is associated with a higher incidence of grade 3/4 myelosuppression, constitutional symptoms, and GI and dermatologic toxicities.
Journal ArticleDOI
Lack of Expression of Thy-1 (CD90) on Acute Myeloid Leukemia Cells With Long-Term Proliferative Ability In Vitro and In Vivo
TL;DR: The results suggest that while heterogeneity exists between individual patients, the leukemic progenitor cells that are capable of maintaining the disease in vitro and in vivo differ from normal hematopoietic progenitors cells in their lack of expression of Thy-1.